Author: Peri Ballantyne Publisher: Routledge ISBN: 1000384004 Category : Medical Languages : en Pages : 216
Book Description
Increasingly, pharmaceuticals are available as the solutions to a wide range of human health problems and health risks, minor and major. This book portrays how pharmaceutical use is, at once, a solution to, and a difficulty for, everyday life. Exploring lived experiences of people at different stages of the life course and from different countries around the world, this collection highlights the benefits as well as the challenges of using medicines on an everyday basis. It raises questions about the expectations associated with the use of medications, the uncertainty about a condition or about the duration of a medicine regimen for it, the need to negotiate the stigma associated with a condition or a type of medicine, the need to access and pay for medicines and the need to schedule medicine use appropriately, and the need to manage medicines’ effects and side effects. The chapters include original empirical research, literature review and theoretical analysis, and convey the sociological and phenomenological complexity of ‘living pharmaceutical lives’. This book is of interest to all those studying and researching social pharmacy and the sociology of health and illness.
Author: Laurence Monnais Publisher: Cambridge University Press ISBN: 1108474667 Category : History Languages : en Pages : 291
Book Description
Innovative examination of the early globalization of the pharmaceutical industry, arguing that colonialism was crucial to the worldwide diffusion of modern medicines.
Author: Rebecca Skloot Publisher: Crown ISBN: 0307589382 Category : Science Languages : en Pages : 386
Book Description
#1 NEW YORK TIMES BESTSELLER • “The story of modern medicine and bioethics—and, indeed, race relations—is refracted beautifully, and movingly.”—Entertainment Weekly NOW A MAJOR MOTION PICTURE FROM HBO® STARRING OPRAH WINFREY AND ROSE BYRNE • ONE OF THE “MOST INFLUENTIAL” (CNN), “DEFINING” (LITHUB), AND “BEST” (THE PHILADELPHIA INQUIRER) BOOKS OF THE DECADE • ONE OF ESSENCE’S 50 MOST IMPACTFUL BLACK BOOKS OF THE PAST 50 YEARS • WINNER OF THE CHICAGO TRIBUNE HEARTLAND PRIZE FOR NONFICTION NAMED ONE OF THE BEST BOOKS OF THE YEAR BY The New York Times Book Review • Entertainment Weekly • O: The Oprah Magazine • NPR • Financial Times • New York • Independent (U.K.) • Times (U.K.) • Publishers Weekly • Library Journal • Kirkus Reviews • Booklist • Globe and Mail Her name was Henrietta Lacks, but scientists know her as HeLa. She was a poor Southern tobacco farmer who worked the same land as her slave ancestors, yet her cells—taken without her knowledge—became one of the most important tools in medicine: The first “immortal” human cells grown in culture, which are still alive today, though she has been dead for more than sixty years. HeLa cells were vital for developing the polio vaccine; uncovered secrets of cancer, viruses, and the atom bomb’s effects; helped lead to important advances like in vitro fertilization, cloning, and gene mapping; and have been bought and sold by the billions. Yet Henrietta Lacks remains virtually unknown, buried in an unmarked grave. Henrietta’s family did not learn of her “immortality” until more than twenty years after her death, when scientists investigating HeLa began using her husband and children in research without informed consent. And though the cells had launched a multimillion-dollar industry that sells human biological materials, her family never saw any of the profits. As Rebecca Skloot so brilliantly shows, the story of the Lacks family—past and present—is inextricably connected to the dark history of experimentation on African Americans, the birth of bioethics, and the legal battles over whether we control the stuff we are made of. Over the decade it took to uncover this story, Rebecca became enmeshed in the lives of the Lacks family—especially Henrietta’s daughter Deborah. Deborah was consumed with questions: Had scientists cloned her mother? Had they killed her to harvest her cells? And if her mother was so important to medicine, why couldn’t her children afford health insurance? Intimate in feeling, astonishing in scope, and impossible to put down, The Immortal Life of Henrietta Lacks captures the beauty and drama of scientific discovery, as well as its human consequences.
Author: Martin A. Voet Publisher: BrownWalker Press ISBN: 1627347461 Category : Law Languages : en Pages : 240
Book Description
This Sixth Edition of The Generic Challenge provides important new updates on current regulatory, legal and commercial issues affecting brand and generic pharmaceutical products, including new laws establishing generics for biologics, and changes brought about by the recently enacted America Invents Act. It explains clearly and understandably the roles of patents, FDA regulation of drugs and the Hatch Waxman Act in commercial drug development in light of generic challenges and how improvements in innovative drug products provide benefits to patients while extending the commercial lives of the drugs. There is simply no other book of its kind on this important subject.
Author: Lee Harland Publisher: Elsevier ISBN: 1908818247 Category : Computers Languages : en Pages : 583
Book Description
The free/open source approach has grown from a minor activity to become a significant producer of robust, task-orientated software for a wide variety of situations and applications. To life science informatics groups, these systems present an appealing proposition - high quality software at a very attractive price. Open source software in life science research considers how industry and applied research groups have embraced these resources, discussing practical implementations that address real-world business problems.The book is divided into four parts. Part one looks at laboratory data management and chemical informatics, covering software such as Bioclipse, OpenTox, ImageJ and KNIME. In part two, the focus turns to genomics and bioinformatics tools, with chapters examining GenomicsTools and EBI Atlas software, as well as the practicalities of setting up an 'omics' platform and managing large volumes of data. Chapters in part three examine information and knowledge management, covering a range of topics including software for web-based collaboration, open source search and visualisation technologies for scientific business applications, and specific software such as DesignTracker and Utopia Documents. Part four looks at semantic technologies such as Semantic MediaWiki, TripleMap and Chem2Bio2RDF, before part five examines clinical analytics, and validation and regulatory compliance of free/open source software. Finally, the book concludes by looking at future perspectives and the economics and free/open source software in industry. - Discusses a broad range of applications from a variety of sectors - Provides a unique perspective on work normally performed behind closed doors - Highlights the criteria used to compare and assess different approaches to solving problems
Author: Brian D. Smith Publisher: Routledge ISBN: 0429663773 Category : Medical Languages : en Pages : 100
Book Description
The healthcare professionals who save and extend our lives are helpless without the medicines and technologies that have revolutionised medical care. But the industry that invents, makes and provides these indispensable tools is transforming under the pressure of ageing populations, globalisation and revolutions in biological and information technology. How this industry adapts and evolves is vitally important to every one of us. This book looks inside the heads and hearts of the people who lead the global pharmaceutical and medical technology industry. It describes how they make sense of their markets and the wider life sciences economy. It reveals what they have learned about how to lead large, complex organisations to compete in dynamic, global markets. Leadership in the Life Sciences is essential reading for anyone working in or with the pharmaceutical and medical technology industry and its halo of supporting companies. Written as ten succinct lessons, it gives the reader unique insight into what the industry’s leaders are thinking. Covering topics from leadership to organisational culture, from change management to digital disruption and from competitive strategy to value-creation, each chapter distils the accumulated wisdom of those who lead the complex and turbulent life sciences industry.
Author: C. F. Harrison Publisher: Createspace Independent Publishing Platform ISBN: 9781537090740 Category : Languages : en Pages : 66
Book Description
Regulatory affairs. If you're finishing your academic career and are looking for a job in biotech or pharmaceuticals, you will have seen a thousand advertisements for regulatory affairs managers. But...what exactly is regulatory affairs? What would I be doing? What sort of skills do I need? What do I need to know before I start? This book answers all these questions and more, providing an introduction to the complex world of regulatory affairs. We cover typical tasks; required skills; the ins and outs of the submission process; vital knowledge you'll need to have; and much more. Lost in a sea of acronyms? We've got you covered. Not really sure how regulatory fits into pharmaceutical development? We explain the process. No idea why your new boss keeps going on about module 3.2.P.7? No problem. Whether you're looking for a job, preparing for an interview, or have just started in the field, this book will give you the foundational knowledge you need to succeed.
Author: Jeffrey Robinson Publisher: McClelland & Stewart ISBN: Category : Business & Economics Languages : en Pages : 282
Book Description
The major pharmaceutical companies, according to John le Carré – who has based his novel The Constant Gardener on their depredations – “are engaged in the systematic corruption of the medical profession, country by country.” Jeffrey Robinson can back up that charge. In Prescription Games, Jeffrey Robinson exposes the yawning abyss between the claims to altruism made by pharmaceutical companies and the harsh reality of their everyday practice. When the industry claims that the enormous markup they charge for new drugs pays the cost of developing new ones, they don’t say that as much as 80 per cent of R&D money is actually directed at developing drugs designed to compete with existing brands, or at creating variations on drugs whose patents are about to expire – expenditures only the industry itself (and its shareholders) will benefit from. Within the industry, there are “blockbuster” drugs that create vast wealth for the companies that manufacture them. Most are designed to treat conditions that are endemic among prosperous, western populations that can afford them. But there are no blockbuster drugs to treat diseases like tuberculosis, cholera, and malaria that ravage the Third World, because Third World countries can’t afford the prices. People in Africa and Asia die from new strains of tuberculosis while people in Europe and North America are offered expensive treatments for obesity, hair loss, and sexual dysfunction. In this hard-hitting exposé, Robinson also examines the extension of patent protection, the end of generic drug competition in Canada, the Nancy Olivieri scandal (how a drug manufacturer fought to conceal research findings that would damage sales of its product), the illicit drug trade, and espionage among drug manufacturers.
Author: National Academies of Sciences, Engineering, and Medicine Publisher: National Academies Press ISBN: 0309468086 Category : Medical Languages : en Pages : 235
Book Description
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author: Peri Ballantyne
Author: Joseph Dumit
Author: Laurence Monnais
Author: Rebecca Skloot
Author: Martin A. Voet
Author: Lee Harland
Author: Brian D. Smith
Author: C. F. Harrison
Author: Jeffrey Robinson
Author: National Academies of Sciences, Engineering, and Medicine